|Table of Contents|

Research progress on the effect of concomitant medication on efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 12
Page:
2364-2368
Research Field:
Publishing date:

Info

Title:
Research progress on the effect of concomitant medication on efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
Author(s):
ZHANG Yankui; HOU Zhansheng; JIANG Bo
Cadre Medical Department，the Third Affiliated Hospital of Kunming Medical University，Yunnan Kunming 650118，China.
Keywords:
concomitant medication; immune checkpoint inhibitors; non-small cell lung cancer; prognosis; intestinal flora
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.12.034
Abstract:
Although immune checkpoint inhibitors (ICI) can significantly improve the clinical outcome of a significant proportion of patients with advanced non-small cell lung cancer (NSCLC),a large number of patients with NSCLC do not benefit from ICI therapy.Clinically,most NSCLC patients use concomitant medication to treat cancer-related symptoms or complications,among which antibiotics,glucocorticoids,proton pump inhibitors,β-blockers and metformin and other concomitant medications can affect the anti-tumor effect of ICI drugs through different mechanisms.This paper reviewed the related studies of the above-mentioned concomitant drugs in the treatment of ICI in NSCLC,in order to provide theoretical basis for optimizing the individualized treatment strategy for ICI in advanced NSCLC patients.

References:

[1]ZHANG S,SUN K,ZHENG R,et al.Cancer incidence and mortality in China,2015［J］.Journal of the National Cancer Center,2021,1(1):2-11.
[2]SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2022［J］.CA Cancer J Clin,2022,72(1):7-33.
[3]GRANT MJ,HERBST RS,GOLDBERG SB.Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC［J］.Nat Rev Clin Oncol,2021,18(10):625-644.
[4]LARKIN J,CHIARION-SILENI V,GONZALEZ R,et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma［J］.N Engl J Med,2015,373(1):23-34.
[5]ZARETSKY JM,GARCIA-DIAZ A,SHIN DS,et al.Mutations associated with acquired resistance to PD-1 blockade in melanoma［J］.N Engl J Med,2016,375(9):819-829.
[6]BOUTROS C,TARHINI A,ROUTIER E,et al.Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination［J］.Nat Rev Clin Oncol,2016,13(8):473-486.
[7]AFZAL MZ,DRAGNEV K,SARWAR T,et al.Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors［J］.Lung Cancer Manag,2019,8(2):LMT11.
[8]CHALABI M,CARDONA A,NAGARKAR DR,et al.Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors:pooled post hoc analyses of the OAK and POPLAR trials［J］.Ann Oncol,2020,31(4):525-531.
[9]HOPKINS AM,KICHENADASSE G,MCKINNON RA,et al.Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors:post hoc analysis of IMpower150［J］.Br J Cancer,2022,126(1):42-47.
[10]OH MS,GUZNER A,WAINWRIGHT DA,et al.The impact of beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors［J］.Clin Lung Cancer,2021,22(1):e57-e62.
[11]PINATO DJ,KASEB A,WANG Y,et al.Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy［J］.J Immunother Cancer,2020,8(2):e000726.
[12]MCQUADE JL,DANIEL CR,HELMINK BA,et al.Modulating the microbiome to improve therapeutic response in cancer［J］.Lancet Oncol,2019,20(2):e77-e91.
[13]HAKOZAKI T,RICHARD C,ELKRIEF A,et al.The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer［J］.Cancer Immunol Res,2020,8(10):1243-1250.
[14]DEROSA L,HELLMANN MD,SPAZIANO M,et al.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer［J］.Ann Oncol,2018,29(6):1437-1444.
[15]TINSLEY N,ZHOU C,TAN G,et al.Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer［J］.Oncologist,2020,25(1):55-63.
[16]KIM H,LEE JE,HONG SH,et al.The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment:a retrospective study［J］.BMC Cancer,2019,19(1):1100.
[17]AHMED J,KUMAR A,PARIKH K,et al.Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors［J］.Oncoimmunology,2018,7(11):e1507670.
[18]HAMADA K,YOSHIMURA K,HIRASAWA Y,et al.Antibiotic usage reduced overall survival by over 70% in non-small cell lung cancer patients on anti-PD-1 immunotherapy［J］.Anticancer Res,2021,41(10):4985-4993.
[19]GALLI G,TRIULZI T,PROTO C,et al.Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer［J］.Lung Cancer,2019,132:72-78.
[20]CORTELLINI A,DI MAIO M,NIGRO O,et al.Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy［J］.J Immunother Cancer,2021,9(4):e002421.
[21]DEROSA L,ROUTY B,THOMAS AM,et al.Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer［J］.Nat Med,2022,28(2):315-324.
[22]MATSON V,FESSLER J,BAO R,et al.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients［J］.Science,2018,359(6371):104-108.
[23]BARUCH EN,YOUNGSTER I,BEN-BETZALEL G,et al.Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients［J］.Science,2021,371(6529):602-609.
[24]HAYWOOD A,DUC J,GOOD P,et al.Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults［J］.Cochrane Database Syst Rev,2019,2(2):CD012704.
[25]HAANEN J,CARBONNEL F,ROBERT C,et al.Management of toxicities from immunotherapy:ESMO clinical practice guidelines for diagnosis,treatment and follow-up［J］.Ann Oncol,2017,28(suppl_4):iv119-iv142.
[26]ARBOUR KC,MEZQUITA L,LONG N,et al.Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer［J］.J Clin Oncol,2018,36(28):2872-2878.
[27]RICCIUTI B,DAHLBERG SE,ADENI A,et al.Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications［J］.J Clin Oncol,2019,37(22):1927-1934.
[28]RIUDAVETS M,MOSQUERA J,GARCIA-CAMPELOR,et al.Immune-related adverse events and corticosteroid use for cancer-related symptoms are associated with efficacy in patients with non-small cell lung cancer receiving anti-PD-(L)1 blockade agents［J］.Front Oncol,2020,10:1677.
[29]DE GIGLIO A,MEZQUITA L,AUCLIN E,et al.Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients under immune-checkpoint inhibitors (ICI)［J］.Cancers (Basel),2020,12(10):2827.
[30]SKRIBEK M,ROUNIS K,AFSHAR S,et al.Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors［J］.Eur J Cancer,2021,145:245-254.
[31]CAIN DW,CIDLOWSKI JAJNRI.Immune regulation by glucocorticoids［J］.Nat Rev Immunol,2017,17(4):233-247.
[32]FUCA G,GALLI G,POGGI M,et al.Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors［J］.ESMO Open,2019,4(1):e000457.
[33]WANG Y,YANG M,TAO M,et al.Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment［J］.Int Immunopharmacol,2021,99:108031.
[34]KEDIKA RR,SOUZA RF,SPECHLER SJ.Potential anti-inflammatory effects of proton pump inhibitors:a review and discussion of the clinical implications［J］.Dig Dis Sci,2009,54(11):2312-2317.
[35]BRUNO G,ZACCARI P,ROCCO G,et al.Proton pump inhibitors and dysbiosis:Current knowledge and aspects to be clarified［J］.World J Gastroenterol,2019,25(22):2706-2719.
[36]TOMITA Y,GOTO Y,SAKATA S,et al.Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors［J］.Oncoimmunology,2022,11(1):2081010.
[37]LUGINI L,FEDERICI C,BORGHI M,et al.Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect［J］.J Enzyme Inhib Med Chem,2016,31(4):538-545.
[38]AFZAL MZ,SHIRAI K.What impact do the proton pump inhibitors have on the efficacy of immune check point inhibitors in metastatic malignant melanoma［J］.Journal of Clinical Oncology,2019,37(15_suppl):e21040.
[39]ANTONI MH,DHABHAR FS.The impact of psychosocial stress and stress management on immune responses in patients with cancer［J］.Cancer,2019,125(9):1417-1431.
[40]NILSSON MB,LE X,HEYMACH JV.β-adrenergic signaling in lung cancer:a potential role for beta-blockers［J］.Journal of Neuroimmune Pharmacology,2020,15(5):1-10.
[41]GUERESCHI MG,ARAUJO LP,MARICATO JT,et al.Beta2-adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA-dependent manner［J］.Eur J Immunol,2013,43(4):1001-1012.
[42]JIN J,WANG X,WANG Q,et al.Chronic psychological stress induces the accumulation of myeloid-derived suppressor cells in mice［J］.PLoS One,2013,8(9):e74497.
[43]SCHARPING NE,MENK AV,WHETSTONE RD,et al.Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia［J］.Cancer Immunol Res,2017,5(1):9-16.
[44]VERDURA S,CUYS E,MARTIN-CASTILLO B,et al.Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy［J］.Oncoimmunology,2019,8(10):e1633235.
[45]OLIVERAS-FERRAROS C,CUF S,VAZQUEZ-MARTIN A,et al.Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation［J］.Cell Cycle,2012,11(5):865-870.
[46]GANDHI L,RODRIGUEZ-ABREU D,GADGEEL S,et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer［J］.N Engl J Med,2018,378(22):2078-2092.

Memo

Memo:
-
Last Update: 1900-01-01